Legal psychedelic therapy is mostly available in research contexts. Switzerland is an exception to this rule: In addition to research projects, the country grants individual treatment permissions for psychedelic therapy. Psychiatrist and psychotherapist Peter Gasser has extensive experience with these forms of therapy: At the turn of the 90s, he had special permission from the Swiss Federal Office for Public Health to research LSD and MDMA. After 2007, he has conducted two studies for LSD-assisted therapy in patients with anxieties due to life-threatening diseases. Since 2014, he has held individual permissions by the Swiss Health Administration for therapy with mind altering substances, which currently also includes psilocybin.

In Nov 2021, Dr. Gasser lectured in a webinar organized by the Finnish Association for Psychedelic Research. Drawing from his own clinical experience and from research projects around the world, Gasser discussed the framework he uses and the conclusions that can currently be made regarding psychedelic therapy.

Born in 1960, psychiatrist and psychotherapist Peter Gasser runs a private practice in Solothurn, Switzerland. He is a husband and a father of three. He was trained in psychodynamic methods as well as in therapy with mind altering drugs, i.e. psycholytic or psychedelic therapy. He has been a member of the Swiss Medical Society for Psycholytic Therapy since 1992 and its president since 1996.

• • • • •

The Finnish Association for Psychedelic Research is a multidisciplinary association founded in December 2016 with the goals of promoting scientific research related to psychedelics and the availability of accessible information based on such research.

More on Psyty: https://psyty.fi

Our social media channels:
http://facebook.com/psyty
http://twitter.com/psytyfi
http://instagram.com/psyty
http://youtube.com/psyty

Lessons learned from doing therapy with LSD and MDMA – Peter Gasser

Higher Signal: Get Smarter. Faster.